Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
-
Denis S. Fedorinov
,
Karin B. Mirzaev
Abstract
Background:
The focus of the study is to determine the prevalence of CYP2C19 alleles, associated with the risk of changes in the pharmacological response to clopidogrel and proton pump inhibitors in patients with acute coronary syndrome (ACS) and gastric ulcer from Russian and Yakut ethnic groups.
Methods:
The research included 411 patients with ACS (143 Russians and 268 Yakuts) and 204 patients with histologically confirmed gastric ulcer (63 Russians and 141 Yakuts). Genotyping of 681G>A and 636G>A polymorphisms was performed by using polymerase real-time chain reaction.
Results:
In both ethnic groups, Hardy-Weinberg equilibrium was followed in a distribution of alleles and genotypes in the population (p>0.05). The 681A allele frequency in the Yakut ethnic group was higher than in the Russian group: 17.53% vs. 8.39% (p=0.001). No statistically significant difference was found in the frequency of 636A in Yakuts and Russians with ACS: 3.92% vs. 3.50% (p=0.840). While comparing the frequency distribution of alleles 681A (13.49% vs. 14.54%, p=0.878) and 636A (7.94% vs. 7.80%, p=1) in patients with a gastric ulcer from Russian and Yakut ethnic groups, no significant difference was found in carrier frequency.
Conclusions:
The results of the present study may be helpful for developing guidelines for CYPC19 genotype-directed antiplatelet therapy for Yakut and Russian patients.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2011;12:873–88.10.2217/pgs.11.4Search in Google Scholar PubMed
2. Sim S, Risinger C, Dahl M, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103–13.10.1016/j.clpt.2005.10.002Search in Google Scholar PubMed
3. Goldstein J. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349–55.10.1046/j.0306-5251.2001.01499.xSearch in Google Scholar PubMed PubMed Central
4. Cardoso R, Benjo A, DiNicolantonio J, Garcia D, Macedo F, El-Hayek G, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart 2015;2:e000248.10.1136/openhrt-2015-000248Search in Google Scholar PubMed PubMed Central
5. Trenk D, Hochholzer W, Fromm M, Chialda L, Pahl A, Valina C, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925–34.10.1016/j.jacc.2007.12.056Search in Google Scholar PubMed
6. Sibbing D, Koch W, Gebhard D, Braun S, Stegherr J, Morath T, et al. Response to letter regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;122:e479.10.1161/CIRCULATIONAHA.110.967158Search in Google Scholar
7. Strand D, Kim D, Peura D. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver 2017;11:27–37.10.5009/gnl15502Search in Google Scholar PubMed PubMed Central
8. Kuo C, Lu C, Shih H, Liu C, Wu M, Hu H, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014;20:16029.10.3748/wjg.v20.i43.16029Search in Google Scholar PubMed PubMed Central
9. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006;44:297–302.10.5414/CPP44297Search in Google Scholar PubMed
10. Denisenko N, Sychev D, Sizova Z, Smirnov V, Ryzhikova K, Sozaeva Z, et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmacogenomics Pers Med 2017;10:253–9.10.2147/PGPM.S141935Search in Google Scholar PubMed PubMed Central
11. Deshpande N, Sharanya V, Kanth R, Murthy H, Sasikala M, Banerjee R, et al. Rapid and ultra-rapid metabolizers with CYP2C19 *17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene 2016;9:159–64.10.1016/j.mgene.2016.06.004Search in Google Scholar
12. Li X. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7.10.1124/dmd.32.8.821Search in Google Scholar
13. Bhatt D, Cryer B, Contant C, Cohen M, Lanas A, Schnitzer T, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–17.10.1056/NEJMoa1007964Search in Google Scholar
14. Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94:317–23.10.1038/clpt.2013.105Search in Google Scholar
15. Mirzaev K, Zelenskaya E, Barbarash O, Ganyukov V, Apartsin K, Saraeva N, et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmacogenomics Pers Med 2017;10:107–14.10.2147/PGPM.S126305Search in Google Scholar
16. Sychev D, Denisenko N, Sizova Z, Grachev A, Velikolug K. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmacogenomics Pers Med 2015;8:111–4.10.2147/PGPM.S78986Search in Google Scholar
17. Giusti B, Gori A, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806–11.10.1016/j.amjcard.2008.11.048Search in Google Scholar
18. Mega J, Close S, Wiviott S. Cytochrome P-450 polymorphisms and response to clopidogrel. J Vasc Surg 2009;49:1083.10.1016/j.jvs.2009.02.023Search in Google Scholar
19. Bonello L, Armero S, Ait Mokhtar O, Mancini J, Aldebert P, Saut N, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010;56:1630–6.10.1016/j.jacc.2010.07.004Search in Google Scholar
20. Collet J, Hulot J, Pena A, Villard E, Esteve J, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309–17.10.1016/S0140-6736(08)61845-0Search in Google Scholar
21. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251–9.10.2217/14622416.9.9.1251Search in Google Scholar PubMed
22. All-Russian Population Census 2010. The national composition of the population of Russia 2010. Available at: http://www.gks.ru/free_doc/new_site/population/demo/per-itog/tab5.xls. Accessed: 12 Jan 2018.Search in Google Scholar
23. Information materials on the final results of the 2010 All-Russia Population Census. Available at: http://www.gks.ru/free_doc/new_site/perepis2010/perepis_itogi1612.htm. Accessed: 12 Jan 2018.Search in Google Scholar
24. Crubézy E, Amory S, Keyser C, Bouakaze C, Bodner M, Gibert M, et al. Human evolution in Siberia: from frozen bodies to ancient DNA. BMC Evol Biol 2010;10:25.10.1186/1471-2148-10-25Search in Google Scholar PubMed PubMed Central
25. Pugach I, Matveev R, Spitsyn V, Makarov S, Novgorodov I, Osakovsky V, et al. The complex admixture history and recent southern origins of Siberian populations. Mol Biol Evol 2016;33:1777–95.10.1093/molbev/msw055Search in Google Scholar PubMed PubMed Central
26. Elhaik E, Tatarinova T, Chebotarev D, Piras I, Calò C, De Montis A, et al. Corrigendum: geographic population structure analysis of worldwide human populations infers their biogeographical origins. Nat Commun 2016;7:13468.10.1038/ncomms13468Search in Google Scholar PubMed PubMed Central
27. Gaikovitch E, Cascorbi I, Mrozikiewicz P, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303–12.10.1007/s00228-003-0606-2Search in Google Scholar PubMed
28. Mirzaev K, Sychev D, Karkischenko V. CYP2C19*2, CYP2C19*3, CYP2C19*17 Allele and genotype frequencies in clopidogrel-treated patients with coronary heart disease from the Russian population. Biomedicine 2013;1:117–28 (in Russian).Search in Google Scholar
29. Makeeva O, Stepanov V, Puzyrev V, Goldstein D, Grossman I. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics 2008;9:847–68.10.2217/14622416.9.7.847Search in Google Scholar PubMed
30. Vasilyev F, Danilova D, Kaimonov V, Chertovskih Y, Maksimova N. Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population. Res Pharmaceut Sci 2016;11:259–64.Search in Google Scholar
31. Sychev D, Arutyunyan G. Cytochrome 2C19 enzyme polymorphism frequency in different indigenous ethnic groups in Russian Federation: a systematic review. J Pharmacogen Pharmacoproteom 2013;05:136.10.4172/2153-0645.1000136Search in Google Scholar
32. Kantemirova B, Timofeeva N, Sychev D. A comparative study of CYP2C19 gene polymorphism in children living in the Astrakhanian region. Astrahanskij Z 2011;4:85–9 (in Russian).Search in Google Scholar
33. Khalikova A, Arkhipova A, Ahmetov I. The study of cytochrome P-450 CYP2C19 gene polymorphisms in population of Tatars living in Republic of Tatarstan. Prakticheskaja Med 2012;3:53–5 (in Russian).Search in Google Scholar
34. Romodanovsky D, Khapaev B, Ignatievet V. Frequencies the “slow” allele variants of the genes coding isoenzymes of cytochrome Р450 CYP2D6, CYP2C19, CYP2C9 in Karachaevs and Circassians. Biomedicina 2010;2:33–7 (in Russian).Search in Google Scholar
35. Mirzayev K, Mammayev S, Gafurov D, Kazakov R, Sychev D. Prevalence of CYP2C19*2 (cG681A,rs4244285) polymorphic markers in Dagestan mountaineers population, its role for pharmacotherapy individualization. Rossijskie Med Vesti 2014;2:57–62 (in Russian).Search in Google Scholar
36. Brackbill M, Kidd R, Abdoo A, Warner J, Harralson A. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels 2009;24:73–8.10.1007/s00380-008-1085-2Search in Google Scholar PubMed
37. Teixeira R, Monteiro P, Marques G, Pego J, Lourenço M, Tavares C, et al. CYP2C19*2 and prognosis after an acute coronary syndrome: insights from a Portuguese center. Rev Portuguesa Cardiol 2012;31:265–73.10.1016/j.repc.2012.02.001Search in Google Scholar PubMed
38. Bathum L, Hansen T, Hørder M, Brøsen K. A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry. Ther Drug Monit 1998;20:1–6.10.1097/00007691-199802000-00001Search in Google Scholar PubMed
39. Aynacioglu A, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66:185–92.10.1053/cp.1999.v66.100072001Search in Google Scholar PubMed
40. Scordo M. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195–200.10.1016/j.phrs.2004.01.004Search in Google Scholar PubMed
41. Wang X, Shen C, Wang B, Huang X, Hu Z, Li J. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene 2015;558:200–7.10.1016/j.gene.2014.12.051Search in Google Scholar PubMed
42. Roh H, Dahl M, Tybring G, Yamada H, Cha Y, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547–51.10.1097/00008571-199612000-00008Search in Google Scholar PubMed
43. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996;6:265–7.10.1097/00008571-199606000-00011Search in Google Scholar PubMed
44. Tantray J, Reddy K, Jamil K, Kumar Y. Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy. Int J Cardiol 2017;229:113–8.10.1016/j.ijcard.2016.11.217Search in Google Scholar PubMed
45. Polonikov A, Kharchenko A, Bykanova M, Sirotina S, Ponomarenko I, Bocharova A, et al. Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. Gene 2017;627:451–9.10.1016/j.gene.2017.07.004Search in Google Scholar PubMed
46. Mega J, Simon T, Collet J, Anderson J, Antman E, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 2010;304:1821.10.1001/jama.2010.1543Search in Google Scholar PubMed PubMed Central
47. Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A, Mulder H, et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 2011;89:662–73.10.1038/clpt.2011.34Search in Google Scholar PubMed
48. Hillman L, Yadlapati R, Thuluvath A, Berendsen M, Pandolfino J. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus 2017;30:1–15.10.1093/dote/dox055Search in Google Scholar PubMed PubMed Central
©2018 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Editorial
- New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics
- Original Articles
- Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies
- Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients
- Effect of the African-specific promoter polymorphisms on the SLC22A2 gene expression levels
- Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
- Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
- Case Report
- Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
Articles in the same Issue
- Frontmatter
- Editorial
- New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics
- Original Articles
- Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies
- Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients
- Effect of the African-specific promoter polymorphisms on the SLC22A2 gene expression levels
- Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
- Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
- Case Report
- Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
